Progesterone was administered percutaneously to postmenopausal women in topical applications on the breast and chest areas in a hydrophilic (gel), lipophilic and an emulsion type base. Venous blood samples were taken 2, 4, 6, 24, 48 and 72 h following administration. The plasma levels were evaluated by radioimmunoassay. Time of maximum concentration (tmax) was, in all cases, in the neighborhood of 4 h. Mean peak plasma concentrations were: 1 ng/ml for the lipophilic, 1.24 ng/ml for the hydrophilic and 2.26 ng/ml for the emulsion type base. The areas under the curves (AUCs) were practically equivalent for the first two methods, but higher values were obtained for administration in the emulsion type base. The elimination was slow, with a half-time varying in the range of 30–40 h for all three types of base, a value that was much higher than those obtained after administration of progesterone via vaginal suppositories. The AUCs were parallel with the peak plasma concentrations: almost 2-fold higher for emulsion than for the gel and lipophilic base. Fit for plasma levels using mono-, bi- and tricompartmental models furnished acceptable results only in the case of monocompartmental model, which raises a number of physiological and physico-chemical considerations. A ‘pseudomonocompartmental’ model was constructed to explain this ‘anomaly’.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
Mauvais-Jarvis P., Vickers C.F.H., Wepierre J. (Eds) (1980): Percutaneous absorption of steroids. London: Academic Press.
Kincl F.A., Ciaccio L.A., Benagiano G. (1978): Increasing oral bioavailability of progesterone by formulation. J. Steroid Biochem., 9, 83–84.
Nillius S.J., Johansson E.D.B. (1971): Plasma levels of progesterone after vaginal, rectal or intramuscular administration of progesterone. Am. J. Obstet. Gynecol., 110, 470–477.
Maddocks S., Hahn P., Moller F., Reid R.L. (1986): A double-blind placebo-controlled trial of progesterone vaginal suppositories in the treatment of premenstrual syndrome. Am. J. Obstet. Gynecol., 154, 573–576.
Mircioiu C., Perju A., Griu E., Calin G., Neagu A., Enachescu D. (1998): Pharmacokinetics of progesterone in postmenopausal women. 1. Pharmacokinetics following intravaginal administration. Eur. J. Drug Metab. Pharmacokinet., 23, 391–396.
Heinzel G., Woloszczak R., Thomann P. (1993): Pharmacokinetic and pharmacodynamic data analysis system. Stuttgart: Gustav Fischer.
Mircioiu C., Perju A., Enachescu D., Griu E., Neagu A. (1993): Biodisposition and pharmacokinetics of percutaneous and intravaginal progesterone. Correlation with in vitro measurements. Third International Conference on Prediction penetration, La Grande Motte, France, 14–16 April 1993.
Morville R., Dray F., Regnier J., Barrat J. (1982): Biodisponibilité de la Progesterone naturelle administré par voie orale. Mesuré de la conc. du steroid dans le plasma, l’endometre et la tissue mammaire. J. Gynecol. Obstet. Biol. Reprod., 11, 55–63.
Thijssen J.H., Zander J. (1966): Progesteron 4C and its metabolites in the blood after intravenous injections into woman. Acta Endocrinol., 51, 563–567.
Siddiqui O., Roberts M., Polack A.E. (1989): Percutaneous absorption of steroids: relative contributions of epidermal penetration and dermal clearance. J. Pharmacokinet. Biopharmacol., 17, 405–424.
Archer D.F., Fahy G.E., Viniegra-Sibal A. (1995): Initial and steady-state pharmacokinetics of a vaginally administered formulation of progesterone. Am. J. Obstet. Gynecol., 173, 471–478.
Rights and permissions
About this article
Cite this article
Mircioiu, C., Perju, A., Griu, E. et al. Pharmacokinetics of progesterone in postmenopausal women. Eur. J. Drug Metab. Pharmacokinet. 23, 397–402 (1998). https://doi.org/10.1007/BF03192300
- percutaneous administration